PROGRAM E (SESSIONS 31-38) - NEW DEVELOPMENTS IN MEDICAL TREATMENTS AND NEW DRUGS; PROGRESS IN ANTI- ATHEROGENIC AND ANTI-HYPERTENSIVE TREATMENTS; MANAGEMENT OF ENDOLEAKS; RECORDED LIVE CASES FROM LEADING CENTERS IN THE US AND EU; ISSUES OF INTEREST;
OUTPATIENT AND OFFICE BASED VASCULAR TREATMENT; TOPICS RELATED TO GOVERNMENT, REIMBURSEMENT, THE SVS, VQI, FDA, GUIDELINES, TRIALS AND EVIDENCE BASED MEDICINE
Location: Grand Ballroom West, 3rd Floor
Location: Grand Ballroom West, 3rd Floor
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT
Location: Grand Ballroom West, 3rd Floor
Moderators: Caron B. Rockman, MD / Ron Waksman, MD / Paulo E. Ocke Reis, MD, PhD
Moderators: Caron B. Rockman, MD / Ron Waksman, MD / Paulo E. Ocke Reis, MD, PhD
6:52 AM - 6:57 AM
Advances In The Use Of Anticoagulant, Antithrombotic And Antiplatelet Drugs In Vascular Patients: What Are The Next Generation Drugs And How Do They Help As Baseline Treatment And Peri-Procedurally
Presenter(s): Elliot L. Chaikof, MD, PhD Location: Grand Ballroom West, 3rd Floor
View Slides in PDF
6:58 AM - 7:03 AM
Best Preoperative Preparation To Prevent Postoperative Myocardial Infarctions (MIs) With Vascular Surgery Or Endo Interventions: What Tests, What Drugs, What Invasive Coronary Procedures Before Or After The Vascular Procedure
Presenter(s): Peter Henke, MD Location: Grand Ballroom West, 3rd Floor
View Slides in PDF
7:04 AM - 7:09 AM
All Acute Adverse Events From Arteriosclerosis (Stroke, MI, ALI) Depend On Thrombosis: This Explains The Positive Outcomes From The Use Of Rivaroxaban In The VOYAGER And COMPASS Trials: Recent VOYAGER Data Show That Rivaroxaban Improves Claudication Symptoms
Presenter(s): Anthony J. Comerota, MD, FACS, FACC Location: Grand Ballroom West, 3rd Floor
View Slides in PDF
7:10 AM - 7:15 AM
The Risk Of Arteriosclerosis And Its Complications Are Increased By LDL Cholesterol (LDL-C) Levels: What Are The Best Medical Strategies To Decrease These Complications: Statins, Adjunctive LDL-C Lowering Drugs - Inclisiran, Bempedoic Acid, Ezetimibe, PCSK-9 Inhibitors, Lepodisiran, Colchicine, Olezarsen: How They Should Be Administered
Presenter(s): Richard Bulbulia, MA, MD, FRCS Location: Grand Ballroom West, 3rd Floor
View Slides in PDF
7:16 AM - 7:21 AM
The Importance Of Decreasing Inflammation (As Reflected By C-Reactive Protein Levels) With Old And New Drugs; New Information On The Effect Of Elevated Lp(a) And Elevated Triglycerides: What Drugs Can Lower Them (Mulvalapin And Zerlasiran; Vascepa)
Presenter(s): Ron Waksman, MD Location: Grand Ballroom West, 3rd Floor
View Slides in PDF
7:22 AM - 7:27 AM
The Importance Of LDL-C Lowering During A Lifetime And In Decreasing Dementia Risk: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins: Why And How Often Should LDL-C Levels Be Measured
Presenter(s): Clayton J. Brinster, MD / J. David Spence, MD Location: Grand Ballroom West, 3rd Floor
View Slides in PDF
7:28 AM - 7:33 AM
Update On The New Anti-Atherosclerosis Vaccine (AtheroVax): A Drug To Produce Lifelong LDL-C Lowering With A Single Gene Modifying Treatment: The Heart-1 Gene-Editing Trial: How Does AtheroVax Work And Results To Date
Presenter(s): Ron Waksman, MD / Nicholas Kipshidze, MD, PhD, DSc Location: Grand Ballroom West, 3rd Floor
View Slides in PDF
7:34 AM - 7:42 AM
Panel Discussion
Location: Grand Ballroom West, 3rd Floor